celastrol has been researched along with Degenerative Disc Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, JX; Chen, XB; Chen, Y; Gu, YT; Shi, KS; Wang, XY; Wu, YS; Xie, JJ; Xuan, J; Zhang, XL; Zheng, ZM | 1 |
1 other study(ies) available for celastrol and Degenerative Disc Disease
| Article | Year |
|---|---|
Celastrol reduces IL-1β induced matrix catabolism, oxidative stress and inflammation in human nucleus pulposus cells and attenuates rat intervertebral disc degeneration in vivo.
Topics: ADAMTS5 Protein; Aggrecans; Animals; Cell Death; Cell Nucleus; Cell Survival; Collagen Type II; Cyclooxygenase 2; Cytoprotection; Extracellular Matrix; Gene Expression Regulation; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Intervertebral Disc Degeneration; Magnetic Resonance Imaging; Male; NF-kappa B; Nitric Oxide Synthase Type II; Nucleus Pulposus; Oxidative Stress; Pentacyclic Triterpenes; Protein Transport; Rats, Sprague-Dawley; RNA, Messenger; Transforming Growth Factor beta; Triterpenes; Tumor Necrosis Factor-alpha | 2017 |